...
首页> 外文期刊>Journal of International Medical Research >Multi-Centre Double-Blind Comparison of Terfenadine Once Daily versus Twice Daily in Patients with Hay Fever
【24h】

Multi-Centre Double-Blind Comparison of Terfenadine Once Daily versus Twice Daily in Patients with Hay Fever

机译:花粉症患者特非那定每日一次和两次两次的多中心双盲比较

获取原文
   

获取外文期刊封面封底 >>

       

摘要

This double-blind, randomized multi-centre study was designed to compare efficacy and tolerability of 120 mg terfenadine taken once daily (in the morning) with the established regimen of 60 mg terfenadine taken twice daily in the treatment of seasonal rhinitis. Two comparable groups, a total of 191 hay fever patients, were treated for 1 week. Symptom severity was assessed by the investigators before and at the end of the treatment (visual analogue scale), and daily by the patient (four-point rating scale). All symptoms improved to a similar degree in both groups. Differences between the two groups were not statistically significant, except for nasal symptoms in three cases as assessed by the visual analogue scale in one centre (better relief in the group given 120 mg terfenadine once daily). Tolerability was good and similar in both groups. The data presented show that in the treatment of hay fever 120 mg terfenadine given once daily is an effective, convenient and well tolerated alternative to the regimen of 60 mg terfenadine given twice daily.
机译:这项双盲,随机,多中心研究旨在比较每天(早晨)服用一次120毫克特非那定与确定的季节性鼻炎每天服用两次的60毫克特非那定的疗效和耐受性。两组共191名花粉症患者进行了1周的比较。研究者在治疗之前和结束时评估症状的严重程度(视觉模拟量表),每天由患者评估(四分等级量表)。两组的所有症状均有相似程度的改善。两组之间的差异无统计学意义,除了三例患者的鼻部症状(通过一个中心的视觉模拟量表评估)(每天一次给予120 mg特非那定的组可更好地缓解症状)。两组的耐受性良好且相似。呈现的数据表明,在花粉症的治疗中,每天一次服用120毫克特非那定是每天两次两次服用60毫克特非那定的一种有效,方便且耐受性良好的替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号